Full Text View
Tabular View
No Study Results Posted
Related Studies
The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)
This study has been completed.
Study NCT00041704   Information provided by Pfizer
First Received: July 12, 2002   Last Updated: October 17, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Candidiasis
More general conditions related to this trial
Mycoses
Interventions listed in this trial
Anidulafungin, VER002
Additional drug interventions recognized in this trial
Anidulafungin
Echinocandins
More general drug interventions related to this trial
Anti-Infective Agents
Antibiotics, Antifungal
Antifungal Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Pfizer
Vicuron Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services